Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01218204 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 287
- Enrollment target
NCT01218204 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 287 participants.
The verdict
NCT01218204, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 287 participants
- Enrollment target
Study Summary
This study investigates the safety, pharmacokinetics and effects of GSK1292263 when taken alone or when co-dosed with atorvastatin to subjects with dyslipidemia.
Interventions
- DRUG 10mg atorvastatin
- DRUG 80mg atorvastatin
- DRUG GSK1292263 Placebo
- DRUG 100mg GSK1292263
- DRUG 300mg GSK1292263
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 287 participants |
| Start Date | 2010-09-14 |
| Est. Completion | 2011-06-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01218204
The ClinicalTrials.gov registry entry for NCT01218204 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 287 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which 10mg atorvastatin is the first listed.
NCT01218204 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01218204 about?
NCT01218204 is a clinical study titled "A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin". This study investigates the safety, pharmacokinetics and effects of GSK1292263 when taken alone or when co-dosed with atorvastatin to subjects with dyslipidemia.
What is the current status of trial NCT01218204?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 287 participants. The study started on 2010-09-14. Estimated completion is 2011-06-29.
What interventions are being tested in trial NCT01218204?
The interventions under investigation include: 10mg atorvastatin (DRUG), 80mg atorvastatin (DRUG), GSK1292263 Placebo (DRUG), 100mg GSK1292263 (DRUG), 300mg GSK1292263 (DRUG).
Who is sponsoring clinical trial NCT01218204?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.